Skip to main content
. 2021 May 28;16(17):2650–2668. doi: 10.1002/cmdc.202100204

Figure 4.

Figure 4

All the candidate inhibitor compounds of the compound library (DC00DC21) were successively used to treat a panel of four different cancer cell lines: A172, A375, MCF7, and U87. Each compound (DC00DC21) was assessed at two different concentrations (doses) 250 μM and 500 μM).